Ovid Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ovid Therapeutics, Inc.
In accepting Scrip’s Lifetime Achievement Award, Ovid Therapeutics’ CEO called on pharma to show responsible leadership and live up to its potential to do good for society.
Eisai and Lilly were the biggest winners at the 19th Annual Scrip Awards in a glittering ceremony at the Dorchester in London’s Mayfair, hosted by the actor and comedian Jon Culshaw.
Ovid anticipates its deal to sell part of its interest in soticlestat milestones and royalties to Ligand will take it through 2026, while it looks to develop its KCC2-targeting OV350 for psychiatric disorders.
Public Company Edition: PTC sold more of its Evrysdi royalties to Royalty Pharma for $1bn. Abivax gained $235.8m in an IPO and concurrent private placement, while Cerevel grossed $450m and Nuvalent and Ultragenyx raised $300m each in follow-on offerings, but Freeline is reviewing strategic options.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.